Mineralys Therapeutics, Inc. Balance Sheet
MLYS / Health Care|3 years of annual SEC 10-K data (FY2022-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Mineralys Therapeutics, Inc. had $206M in total assets and $191M in shareholders' equity as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Cash & Equivalents | $114.1M | $49.3M | $87.7M |
| Current Assets | $205.4M | $249.1M | $112.8M |
| PP&E (Net) | $53.0K | $0 | - |
| Total Assets | $205.9M | $251.6M | $114.4M |
| Current Liabilities | $14.6M | $10.5M | $8.1M |
| Shareholders' Equity | $191.3M | $241.2M | -$52.3M |